Syncona, a leading FTSE250 healthcare company focused on founding, building and funding global leaders in life science, led a CHF35m investment in Anaveon, a new immuno-oncology company. The company invested CHF28m, obtaining a 47% stake. Martin Murphy, Chief Executive of Syncona Investment Management Limited, said: "Our commitment to Anaveon is a great example of our strategy to build truly innovative companies anchored by exceptional science and experienced teams. Anaveon has a strong strategic fit across Syncona's cell therapy portfolio and we are excited by the potential to develop a best-in-class product in the IL-2 space. The Syncona team will work in close partnership with the company's world-leading founders to develop its business plan and clinical pathway."